Announced
Synopsis
Biomed Industries, a bio-pharmaceutical company, offered to acquire Neoleukin Therapeutics, a biotechnology company, for $68m. "We believe our offer is very compelling as it provides Neoleukin's shareholders with a highly certain and significant return and the ability to obtain liquidity for their shares, as well as the upside potential of Biomed," Lloyd L. Tran, Biomed Industries Chairman and CEO.
Show Details & Financials
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.